4.1 Article

Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy

Journal

ANTIVIRAL THERAPY
Volume 16, Issue 2, Pages 253-256

Publisher

INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1748

Keywords

-

Funding

  1. Bristol-Myers Squibb
  2. Cerner Corporation
  3. Gilead Sciences
  4. Merck
  5. Roche
  6. GlaxoSmithKline
  7. Boehringer Ingelheim

Ask authors/readers for more resources

We report the case of an integrase strand-transfer inhibitor (INI)-resistant and four-drug-class-resistant HIV-1 variant infecting an antiretroviral therapy-naive man. The virus harboured INI drug resistance substitutions (Q148H and G140S) along with multiple reverse transcriptase and protease inhibitor resistance mutations. This case illustrates an emerging need to consider the possibility of acquired INI resistance among newly diagnosed treatment-naive individuals harbouring multidrug-resistant HIV-1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available